A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Latest Information Update: 01 Dec 2023
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Solifenacin
- Indications Overactive bladder; Urinary incontinence
- Focus Therapeutic Use
- Sponsors Allergan
- 01 Nov 2023 Results of pooled post hoc analysis (n=1504 from studies NCT00910845, NCT00910520, NCT01767519, NCT01945489) assessing the effects of age, gender, and postvoid residual volume on catheterization rates after treatment with OnabotulinumtoxinA for Overactive Bladder published in the European Urology Open Science
- 17 Oct 2021 Results of a pooled gender-focused analysis assessing long-term safety effects of onabotulinumtoxin A from following clinical studies: NCT00910845, NCT00910520, NCT01767519, NCT01945489 and NCT00915525 presented at the 51st Annual Meeting of the International Continence Society
- 17 Oct 2021 Results (n=1564) of pooled analysis from two pivotal trials (NCT00910845 and NCT00910520) and two post-marketing studies (NCT01767519 and NCT01945489) assessing the efficacy and safety of onabotulinumtoxin A in a sufficient number of male patients with OAB and UI, presented at the 51st Annual Meeting of the International Continence Society.